Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11050MR)

This product GTTS-WQ11050MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11050MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7565MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ15589MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ5840MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ7783MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ1656MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4802MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW